Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?—Experience from a prospective observational study | Zendy

Jie Fang | Zendy; Congqin Chen | Zendy; Yan Wu | Zendy; Min Zhang | Zendy; Ying Zhang | Zendy; Guochao Shi | Zendy; Yijin Yao | Zendy; Hong Chen | Zendy; Xiaolan Bian | Zendy

Open Access

Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?—Experience from a prospective observational study

Author(s) -

Jie Fang,

Congqin Chen,

Yan Wu,

Min Zhang,

Ying Zhang,

Guochao Shi,

Yijin Yao,

Hong Chen,

Xiaolan Bian

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.03.207

Subject(s) - cmin , linezolid , medicine , therapeutic drug monitoring , logistic regression , population , pharmacokinetics , cmax , vancomycin , staphylococcus aureus , environmental health , biology , bacteria , genetics

Our results suggest that the pharmacodynamic range of linezolid can be defined as 2-8 mg/L for the Chinese population. Renal function partially accounts for the inter-interindividual variability of exposure. The application of TDM might be especially valuable in optimizing linezolid exposure in the majority of patients to avoid therapeutic failure and/or dose-dependent adverse reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research